Barbara Jereczek-Fossa, Full Professor of Radiation Oncology at Milan University, Chair of Radiation Oncology at the European Institute of Oncology, Milan, Italy, President Elect of ESTRO, shared a post on LinkedIn:
“Advanced Prostate Cancer Consensus Conference 2026 radiotherapy highlights:
- Early salvage radiotherapy is recognized as the preferred option for most patients with early biochemical recurrence.
- Waiting for higher PSA levels or positive imaging risks losing the window of opportunity for a second cure.
- Radiotherapy to the primary in de novo mHSPC
Now supported in low-volume disease and selected high-volume cases, as part of a multimodal approach. - SBRT / MDT in oligorecurrent and oligoprogressive disease
A major step forward:- Not only PFS benefit, but now also signals of overall survival OS advantage from small randomized data.
Beyond science, also great networking with colleagues and friends.
Compliments to:
Silke Gillessen
Aurelius Omlin and to all panelists, attendees and organizers
for this fantastic multidisciplinary consensus!”
Other articles featuring Barbara Jereczek-Fossa on OncoDaily.
